The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis.

[1]  F. Jornayvaz,et al.  Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link? , 2015, Molecular and Cellular Endocrinology.

[2]  F. Anania,et al.  Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis. , 2015, The Journal of nutritional biochemistry.

[3]  Y. Chawla,et al.  Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. , 2015, Journal of clinical and experimental hepatology.

[4]  A. McCullough,et al.  Renin‐angiotensin system and fibrosis in non‐alcoholic fatty liver disease , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[5]  I. Song,et al.  Nonalcoholic Steatohepatitis Associated With Metabolic Syndrome: Relationship to Insulin Resistance and Liver Histology , 2014, Journal of clinical gastroenterology.

[6]  James E. Nelson,et al.  Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired mitochondrial biogenesis , 2014, Hepatology.

[7]  Aijaz Ahmed,et al.  Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. , 2014, World journal of hepatology.

[8]  K. Chayama,et al.  Efficacy of probucol for the treatment of non‐alcoholic steatohepatitis with dyslipidemia: An open‐label pilot study , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[9]  M. Honda,et al.  The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial , 2014, Diabetologia.

[10]  Z. Halpern,et al.  Non‐alcoholic fatty liver disease independently predicts prediabetes during a 7‐year prospective follow‐up , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[11]  Hiram Beltrán-Sánchez,et al.  Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010. , 2013, Journal of the American College of Cardiology.

[12]  O. Paciello,et al.  Effects of Sodium Butyrate and Its Synthetic Amide Derivative on Liver Inflammation and Glucose Tolerance in an Animal Model of Steatosis Induced by High Fat Diet , 2013, PloS one.

[13]  H. Makhlouf,et al.  Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) , 2013, Digestive Diseases and Sciences.

[14]  Y. Nie,et al.  Association between metabolic syndrome and the development of non-alcoholic fatty liver disease , 2013, Experimental and therapeutic medicine.

[15]  D. Torres,et al.  Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial , 2013, Therapeutic advances in gastroenterology.

[16]  E. Boyko,et al.  Non‐alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: Results of a US national survey in three ethnic groups , 2013, Journal of gastroenterology and hepatology.

[17]  Z. Younossi,et al.  In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. , 2013, Metabolism: clinical and experimental.

[18]  Derek LeRoith,et al.  Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. , 2012, Endocrine-related cancer.

[19]  E. Zoetendal,et al.  Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. , 2012, Gastroenterology.

[20]  G. Musso,et al.  Nonalcoholic steatohepatitis versus steatosis: Adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism , 2012, Hepatology.

[21]  B. Neuschwander‐Tetri,et al.  Dietary trans-Fatty Acid Induced NASH is Normalized Following Loss of trans-Fatty Acids from Hepatic Lipid Pools , 2012, Lipids.

[22]  Qiang Wan,et al.  Lifestyle intervention in non-alcoholic fatty liver disease in Chengyang District, Qingdao, China. , 2012, World journal of hepatology.

[23]  K. Cusi,et al.  Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[24]  James E. Nelson,et al.  Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll‐like receptor activation , 2012, Hepatology.

[25]  Prerna Bhargava,et al.  Role and function of macrophages in the metabolic syndrome. , 2012, The Biochemical journal.

[26]  S. Devaraj,et al.  Increased Toll-Like Receptor Activity in Patients With Metabolic Syndrome , 2012, Diabetes Care.

[27]  G. Musso,et al.  Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials , 2012, Diabetologia.

[28]  Y. Matsuzaki,et al.  Efficacy of pitavastatin for the treatment of non‐alcoholic steatohepatitis with dyslipidemia: An open‐label, pilot study , 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

[29]  Christopher D. Williams,et al.  Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12‐month randomized, prospective, open‐ label trial , 2011, Hepatology.

[30]  F. Karpe,et al.  Fatty Acids, Obesity, and Insulin Resistance: Time for a Reevaluation , 2011, Diabetes.

[31]  D. Leroith,et al.  The metabolic syndrome--from insulin resistance to obesity and diabetes. , 2011, The Medical clinics of North America.

[32]  G. Gores,et al.  Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[33]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[34]  B. Neuschwander‐Tetri,et al.  Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings , 2011, Hepatology.

[35]  D. Brenner,et al.  Role of Toll-Like Receptors and Their Downstream Molecules in the Development of Nonalcoholic Fatty Liver Disease , 2011, Gastroenterology research and practice.

[36]  H. Tilg,et al.  Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis , 2010, Hepatology.

[37]  H. Conjeevaram,et al.  Meta‐analysis: insulin sensitizers for the treatment of non‐alcoholic steatohepatitis , 2010, Alimentary pharmacology & therapeutics.

[38]  F. Berthier,et al.  A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin‐18 for the diagnosis of non‐alcoholic steatohepatitis in morbidly obese patients , 2010, Alimentary pharmacology & therapeutics.

[39]  E. Ford,et al.  Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US * , 2010, Journal of diabetes.

[40]  D. Leroith,et al.  Insulin resistance in obesity as the underlying cause for the metabolic syndrome. , 2010, The Mount Sinai journal of medicine, New York.

[41]  S. Woods,et al.  High‐fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis , 2010, Hepatology.

[42]  M. Stepanova,et al.  Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study , 2010, Gut.

[43]  D. Brenner,et al.  Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. , 2010, Gastroenterology.

[44]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[45]  Hirokazu Takahashi,et al.  Efficacy of ezetimibe for the treatment of non‐alcoholic steatohepatitis: An open‐label, pilot study , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

[46]  P. Rosenthal,et al.  Association Between Metabolic Syndrome and Liver Histology Among Children With Nonalcoholic Fatty Liver Disease , 2010, The American Journal of Gastroenterology.

[47]  K. Petersen,et al.  Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. , 2010, The New England journal of medicine.

[48]  D. S̆timac,et al.  Predictors of nonalcoholic steatohepatitis in patients with elevated alanine aminotransferase activity. , 2010, Collegium antropologicum.

[49]  A. Ananthakrishnan,et al.  A Noninvasive Clinical Scoring Model Predicts Risk of Nonalcoholic Steatohepatitis in Morbidly Obese Patients , 2010, Obesity surgery.

[50]  E. Jackvony,et al.  Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.

[51]  S. Klein,et al.  Pathogenesis and Pathophysiology of the Cardiometabolic Syndrome , 2009, Journal of clinical hypertension.

[52]  E. Gómez,et al.  Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease , 2009, Alimentary pharmacology & therapeutics.

[53]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[54]  F. Pattou,et al.  Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. , 2009, Gastroenterology.

[55]  V. Mohan,et al.  Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. , 2009, Diabetes research and clinical practice.

[56]  Z. Bıyıklı,et al.  Liver histology according to the presence of metabolic syndrome in nonalcoholic fatty liver disease cases. , 2009, World journal of gastroenterology.

[57]  L. Mogoantă,et al.  Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. , 2009, World journal of gastroenterology.

[58]  Kayoung Lee,et al.  The roles of obesity and gender on the relationship between metabolic risk factors and non‐alcoholic fatty liver disease in Koreans , 2009, Diabetes/metabolism research and reviews.

[59]  K. Kasturi,et al.  Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[60]  B. Neuschwander‐Tetri,et al.  Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[61]  G. Aithal,et al.  Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. , 2008, Gastroenterology.

[62]  Alexander Pertsemlidis,et al.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease , 2008, Nature Genetics.

[63]  U. Broedl,et al.  Adipokines and Insulin Resistance , 2008, Molecular medicine.

[64]  S. Kalra.  Disruption in the leptin-NPY link underlies the pandemic of diabetes and metabolic syndrome: new therapeutic approaches. , 2008, Nutrition.

[65]  N. Maeda,et al.  Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis , 2008, Hepatology.

[66]  E. Vittinghoff,et al.  A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients , 2008, Hepatology.

[67]  A. Pocai,et al.  Leptin controls adipose tissue lipogenesis via central, STAT3–independent mechanisms , 2008, Nature Medicine.

[68]  J. Sheeder,et al.  Presence of the metabolic syndrome in obese adolescents predicts impaired glucose tolerance and nonalcoholic fatty liver disease. , 2008, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[69]  J. Cook,et al.  Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. , 2008, European journal of pharmacology.

[70]  Y. Kloog,et al.  The Effect of Ras Inhibition on the Proliferation, Apoptosis and Matrix Metalloproteases Activity in Rat Hepatic Stellate Cells , 2008, Digestive Diseases and Sciences.

[71]  Christopher B. Newgard,et al.  Molecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes , 2008, Nature Reviews Molecular Cell Biology.

[72]  M. Pérez-Carreras,et al.  A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[73]  M. Manco,et al.  Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis , 2008, International Journal of Obesity.

[74]  Long‐Teng Lee,et al.  Metabolic Syndrome Is Related to Nonalcoholic Steatohepatitis in Severely Obese Subjects , 2007 .

[75]  J. Carvalheira,et al.  Loss-of-Function Mutation in Toll-Like Receptor 4 Prevents Diet-Induced Obesity and Insulin Resistance , 2007, Diabetes.

[76]  S. McCall,et al.  Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis , 2007, Hepatology.

[77]  M. Kroh,et al.  Laparoscopic bariatric surgery: what else are we uncovering? Liver pathology and preoperative indicators of advanced liver disease in morbidly obese patients , 2007, Surgical Endoscopy.

[78]  A. Halpern,et al.  Effects of bariatric surgery on nonalcoholic fatty liver disease: Preliminary findings after 2 years , 2007, Journal of gastroenterology and hepatology.

[79]  G. Marchesini,et al.  Metabolic syndrome and NASH. , 2007, Clinics in liver disease.

[80]  P. Turnbaugh,et al.  Microbial ecology: Human gut microbes associated with obesity , 2006, Nature.

[81]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[82]  H. Cortez‐Pinto,et al.  Non-alcoholic steatohepatitis and metabolic syndrome , 2006, Current opinion in clinical nutrition and metabolic care.

[83]  N. Chalasani,et al.  An assessment of statin safety by hepatologists. , 2006, The American journal of cardiology.

[84]  A. Burroughs,et al.  Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study , 2006, Current medical research and opinion.

[85]  D. Pessayre,et al.  Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. , 2006, Mitochondrion.

[86]  B. Neuschwander‐Tetri.  Nonalcoholic steatohepatitis and the metabolic syndrome. , 2005, The American journal of the medical sciences.

[87]  G. Reaven.  Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. , 2005, Panminerva medica.

[88]  G. Pacini,et al.  Adipokines in NASH: Postprandial lipid metabolism as a link between adiponectin and liver disease , 2005, Hepatology.

[89]  G. Pacini,et al.  Hypoadiponectinemia Predicts the Severity of Hepatic Fibrosis and Pancreatic Beta-Cell Dysfunction in Nondiabetic Nonobese Patients with Nonalcoholic Steatohepatitis , 2005, The American Journal of Gastroenterology.

[90]  F. Bäckhed,et al.  Obesity alters gut microbial ecology. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[91]  G. Bedogni,et al.  Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study , 2005, Hepatology.

[92]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[93]  E. Ford.  Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. , 2005, Diabetes care.

[94]  Long‐Teng Lee,et al.  Bright liver and alanine aminotransferase are associated with metabolic syndrome in adults. , 2005, Obesity research.

[95]  D. Pessayre,et al.  NASH: a mitochondrial disease. , 2005, Journal of hepatology.

[96]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[97]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[98]  H. Münzberg,et al.  Molecular and anatomical determinants of central leptin resistance , 2005, Nature Neuroscience.

[99]  E. Ferrannini,et al.  Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms , 2005, Diabetologia.

[100]  Z. Goodman,et al.  Predictors of Nonalcoholic Steatohepatitis and Advanced Fibrosis in Morbidly Obese Patients , 2005, Obesity surgery.

[101]  K. Birkeland,et al.  Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease , 2005, Scandinavian journal of gastroenterology.

[102]  H. Tilg,et al.  Adiponectin and its receptors in non-alcoholic steatohepatitis , 2004, Gut.

[103]  A. McCullough,et al.  The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. , 2004, Clinics in liver disease.

[104]  G. Gores,et al.  Free fatty acids promote hepatic lipotoxicity by stimulating TNF‐α expression via a lysosomal pathway , 2004 .

[105]  J. Shaw,et al.  The metabolic syndrome: prevalence in worldwide populations. , 2004, Endocrinology and metabolism clinics of North America.

[106]  P. Hayashi,et al.  Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis , 2003, American Journal of Gastroenterology.

[107]  B. Neuschwander‐Tetri,et al.  Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR‐γ ligand rosiglitazone , 2003, Hepatology.

[108]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[109]  G. Musso,et al.  Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis , 2003, Hepatology.

[110]  A. Stalenhoef,et al.  The Metabolic Syndrome: Targeting Dyslipidaemia to Reduce Coronary Risk , 2003, Journal of cardiovascular risk.

[111]  A. Moser,et al.  Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease , 2003, Hepatology.

[112]  J. George,et al.  Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: A manifestation of lipotoxicity? , 2002, Hepatology.

[113]  M. Matsuda,et al.  Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. , 2002, Diabetes.

[114]  P. Godowski,et al.  Tissue Expression of Human Toll-Like Receptors and Differential Regulation of Toll-Like Receptor mRNAs in Leukocytes in Response to Microbes, Their Products, and Cytokines , 2002, The Journal of Immunology.

[115]  A. Fukamizu,et al.  Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[116]  G. Marchesini,et al.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.

[117]  Y. Terauchi,et al.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.

[118]  M. Akahoshi,et al.  Correlation between fatty liver and coronary risk factors: a population study of elderly men and women in Nagasaki, Japan. , 2001, Hypertension research : official journal of the Japanese Society of Hypertension.

[119]  S. Lemieux,et al.  Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. , 2001, Diabetes.

[120]  J. Dixon,et al.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. , 2001, Gastroenterology.

[121]  H. Tilg,et al.  Cytokines in alcoholic and nonalcoholic steatohepatitis. , 2000, The New England journal of medicine.

[122]  C. García-Monzón,et al.  Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. , 2000, Journal of hepatology.

[123]  J. Tooke,et al.  Adverse endothelial function and the insulin resistance syndrome , 2000, Journal of internal medicine.

[124]  M. Başaranoǧlu,et al.  A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. , 1999, Journal of hepatology.

[125]  S. Thung,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Liver Pathology and the Metabolic Syndrome X in , 2022 .

[126]  C. Newgard,et al.  Direct antidiabetic effect of leptin through triglyceride depletion of tissues. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[127]  R M Peshock,et al.  Relationship of Generalized and Regional Adiposity to Insulin Sensitivity in Men With NIDDM , 1996, Diabetes.

[128]  L. Mandarino,et al.  Interaction between glucose and free fatty acid metabolism in human skeletal muscle. , 1993, The Journal of clinical investigation.

[129]  G. Reaven.  Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[130]  P. Barter,et al.  Role of triglyceride-rich lipoproteins and hepatic lipase in determining the particle size and composition of high density lipoproteins. , 1986, Journal of lipid research.

[131]  R. DeFronzo,et al.  The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. , 1975, The Journal of clinical investigation.

[132]  A. Kasturiratne,et al.  Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus: results from a prospective, community based, cohort study , 2011 .

[133]  T. Okanoue,et al.  Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease , 2010, Journal of Gastroenterology.

[134]  O. Ilkayeva,et al.  Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. , 2008, Cell metabolism.

[135]  G. Farrell,et al.  LIVER FAILURE AND LIVER DISEASE Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis , 2006 .

[136]  A. Mark,et al.  Obesity-associated hypertension: new insights into mechanisms. , 2005, Hypertension.

[137]  D. Cook,et al.  Metabolic syndrome and renal sodium handling in three ethnic groups living in England , 2003, Diabetologia.

[138]  G. Reaven.  Banting lecture 1988 , 1997 .

[139]  G. Lewis,et al.  Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. , 1995, The Journal of clinical investigation.